Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer


Harold J. Burstein, MD, PhD, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses a survey of how clinicians use genomic assays to assist in decision-making regarding the use of neoadjuvant and adjuvant chemotherapy for patients with ER-positive/HER2-negative early breast cancer.

Related Videos
Related Content